|
|
|
 |
Search published articles |
 |
|
Showing 4 results for Thyroid Cancer
Dr. D. Shahbazi-Gahrouei, S. Nikzad,
Volume 8, Issue 4 (3-2011)
Abstract
Background: Radioiodine therapy has proven to
be an effective method in the treatment of patients
with differentiated thyroid carcinoma after thyroidectomy.
The scope of this study is to describe a method
to obtain the dose of organs using medical internal
radiation dosimetry (MIRD) method. At the end, the
results of MIRD calculations were compared with
thermoluminescent dosimeter (TLD-100). Materials
and Methods: The study was performed on 27
patients using TLD for thyroid, sternum and cervical
vertebra. There were 5 TLDs for each organ which
they were taken after 4, 8, 12, 20 and 24 hr. To
calculate the amount of activity in the thyroid a head
and neck phantom with a source of 10 mCi of 131I
was used. A head and neck phantom was used to
determine the absorbed dose. A source of 10 mCi of
131I was putted on phantom. Several TLDs were
placed on the surface of thyroid on phantom for 24 hr
and then compared with the dose of phantom and
patients followed by calculation of the activity in
patient's thyroid. Finally, MIRD formula was used to
calculate absorbed dose in cervical vertebra and
sternum. Results: The average of measurements of
TLDs on phantom for 10 mCi of iodine was 33.3 cGy.
The absorbed activity in thyroid in three groups for
100, 150 and 175 mCi administered 131I were 94.9,
104.6 and 108.8 mCi cumulated activity in 24 hrs.
The absorbed dose obtained by MIRD calculations
was found to be 419.9, 463.2, and 481.5 for thyroid,
288.9, 252.4 and 252.4 for sternum and 288.9,
252.4 and 252.4 for cervical vertebra. Conclusions:
The results of MIRD method was similar to the results
obtained experimentally. It was shown that 75% of
absorbed dose calculated by the MIRD method is
detectable by the TLD method. Iran. J. Radiat. Res.,
2011 8(4): 249-252
Dr. G.k. Gedik, S. Gedik, B.e. Koktekir, L. Kebapcilar, P.o. Kara,
Volume 12, Issue 4 (10-2014)
Abstract
Background: The therapeutic administration of 131I for thyroid remnant ablation and for metastases comes up with some adverse effects. This study was conducted to investigate whether single high dose radioiodine therapy affects lacrimal gland functions or not. Materials and Methods: Seventy-eight eyes of 39 patients, who were diagnosed as differentiated thyroid carcinoma, were objectively tested with Schiermer’s test and tear film break-up time test before and 1 and 6 months after high dose (&ge 3700 MBq) 131I therapy. Results: The median values of pre-treatment Schiermer’s test were 10.00 mm and 9.60 mm for right and left eyes, respectively. At the post-treatment first and sixth months, no significant change was observed in the median values of Schiermer’s test in both eyes (p= 0.189 and p=0.085, respectively, Friedman test). The median values of pre-treatment tear film break-up time test were 9.15 sn and 9.20 sn for right and left eyes, respectively. The median values of post-treatment tear film break-up times reduced at first and sixth months and the difference between the pre-treatment and post-treatment values were significant in both eyes (p=0.020 and p=0.022 for right and left eyes, respectively, Friedman test). Conclusion: Impairment of goblet cell function occurs early after administration of single high dose 131I application. However, reduction in tear secretion from lacrimal gland is not observed.
Y. Parlak, Dr. M. Demir, I. Cavdar, S. Ereees, G. Gumuser, B. Uysal, G. Capa Kaya, M. Koç, E. Sayit,
Volume 14, Issue 2 (4-2016)
Abstract
Background: Radiation absorbed dose to the red bone marrow, a critical organ in the therapy of thyroid carcinoma, is generally kept below 2 Gy for non-myeloablative therapies. The aim of this study was to calculate bone marrow radiation dose by using MIRDOSE3 package program and to optimize the safe limit of activity to be administered to the thyroid cancer patients. Materials and Methods: In this study, 83 thyroid cancer patients were divided into 3 groups based on the amount of activity administered into the body. In the groups, 3700 MBq, 5550 MBq and 7400 MBq activities were used respectively. The curves of time-activity were drawn from blood samples counts and effective half-life and residence time were calculated. Correlations of bone marrow radiation dose and radioiodine effective half-life were determined as a function of administered activity via ANOVA test. Tg levels and tumour diameters were compared using Spearman’s correlation. Results: The effective half-lives of 131I for three groups of whole-body, receiving 3700 MBq, 5550 MBq and 7400 MBq were calculated as 20.57±5.4, 17.8±5.8 and 18.7±3.9 hours, respectively. The average bone marrow doses for 3 groups of patients were 0.32±0.08 Gy, 0.42±0.14 Gy and 0.60±0.24 Gy, respectively. Conclusion: It was concluded that, the bone marrow dose to the patients still remains within the recommended level even after administering an activity of 7400 MBq of 131I to the patients.
B. Miao, G. Ruan, F. Meng, Q. Zhang, J. Pei, D. Li,
Volume 23, Issue 1 (1-2025)
Abstract
Background: To systematically evaluate the effects of radiofrequency ablation on lymphocytes, subsets, and cytokines in patients with thyroid cancer. Materials and Method: Radiofrequency ablation, thyroid cancer, lymphocytes, and other key terms are used to search for randomized controlled clinical trials (RCTs) related to them.The data analysis is conducted using RevMan 5.3 software. The relative risk (RR) is used to analyze the effect magnitude of binary variable data. The mean difference (MD) represents the continuous variable data results. The interval estimation is presented as 95% CI. Results: The standardized mean difference between the CD3+, CD4+, sub-population counts, and CD4+/CD8+ratios among the studies was 1.91 (95% CI0.91 ~ 2.91), 0.07(95% CI-0.07 ~ 0.22). The combined effect quantity indicated that radiofrequency ablation had a significant effect on improving lymphocytes and sub-populations in thyroid cancer patients.The heterogeneity test results among different studies were I2 = 99%, 99%, P < 0.01 and 0.32. The results indicated a high level of heterogeneity between the two groups. The standardized mean difference of cytokine levels such as IL-6 and TNF-a in different studies was -4.20 (95% CI-4.30 ~ -4.10), -6.40 (95% CI-7.07 ~ -5.77). The combined effect quantity indicated that radiofrequency ablation had a significant effect on reducing serum inflammatory cytokine levels in thyroid cancer patients.The heterogeneity test results between different studies were I2 = 100%, 97%, and P < 0.01. The results indicated a high level of heterogeneity between the two groups. The differences between groups are statistically significant (x2 = 4.48, P < 0.01). Conclusion: Compared with other surgeries, radiofrequency ablation can inhibit CD4+, promote CD8+lymphocyte proliferation, and reduce inflammatory factors in thyroid cancer patients.
|
|
